These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 11025565)
1. "IIb or not IIb or maybe IIb?" Is that the question? Or is it "which IIb and to whom?". Brinker JA Catheter Cardiovasc Interv; 2000 Oct; 51(2):145-6. PubMed ID: 11025565 [No Abstract] [Full Text] [Related]
2. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953 [No Abstract] [Full Text] [Related]
3. Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Parmar R; Stouffer GA Am J Med Sci; 1997 Jul; 314(1):31-6. PubMed ID: 9216438 [No Abstract] [Full Text] [Related]
4. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Iakovou I; Dangas G; Mehran R; Lansky AJ; Kobayashi Y; Adamian M; Polena S; Collins MB; Roubin GS; Stone GW; Leon MB; Moses JW Am J Cardiol; 2002 Apr; 89(8):976-9. PubMed ID: 11950440 [No Abstract] [Full Text] [Related]
5. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects. Reginelli JP; Topol EJ Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193 [No Abstract] [Full Text] [Related]
6. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. van de Werf F Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200 [No Abstract] [Full Text] [Related]
7. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
8. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries. Goldschmidt-Clermont PJ J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856 [No Abstract] [Full Text] [Related]
9. Routine use of abciximab in coronary stenting? Stables RH Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267 [No Abstract] [Full Text] [Related]
10. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Lincoff AM; Topol EJ Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004 [No Abstract] [Full Text] [Related]
11. Avoidance of adverse events in restenotic lesions with abciximab? Linnemeier TJ J Invasive Cardiol; 2000 Nov; 12(11):545-6. PubMed ID: 11060564 [No Abstract] [Full Text] [Related]
12. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. Cheng JW Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710 [TBL] [Abstract][Full Text] [Related]
13. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]